Remove 2023 Remove Leads Remove Pharmacology
article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2023 is set to usher in a new era of genomics, and here are five areas where we should see significant advances. Just one mutation can lead to a complete change in protein formation. The post A new dawn of the genomic age: five areas set to be transformed in 2023 appeared first on.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New radiopharmaceutical laboratory opens in Germany

European Pharmaceutical Review

The facility will also have capacity to conduct non-clinical pharmacology studies for detailed characterisation of its first-in-class development candidates, according to Ariceum. Internet] European Pharmaceutical Review, Issue 3 2023. 1 References Jaafar-Thiel. Meeting rising demands of a new radiotheranostic era. cited 2024Mar].

article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience.

Medicine 102
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. million in sales by 2032. percent sales expected in 2032 within the seven major markets.

article thumbnail

Recurrent drug shortages signal onerous outlook for cardiovascular care

Pharmaceutical Technology

The Australian Department of Health and Aged Care published a similar statement on August 25, stating that tenecteplase shortages will likely affect the country until the end of 2023. But these substitutions do not come without complications, as these drugs can vary in their pharmacologic properties, states Page.

Medicine 111
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. He received an MD from the Georg August University of Göttingen and completed a postdoctoral Master’s in Medical Sciences Clinical Pharmacology at the University of Glasgow.

Patients 105